Giving drug researchers control of their data
Iguess I’ve been digitizing for my entire career, 20 years,” said Michael Montello, senior vice president of R&D technology at GlaxoSmithKline. “I remember the first data warehouse I implemented in discovery . . . And here we are still talking about digital transformation.” Montello was reminiscing at the Bio-IT World Conference in September, where he discussed the past 3 years of GSK’s digitization initiative. Peers from Pfizer, Roche, and Eli Lilly and Company joined him, describing similar programs at their firms in drug discovery data management. Their discussion had a familiar ring to it: break down function silos, establish central data management, develop standard terminologies. In fact, a regular conference attendee may well have shared Montello’s observation: “Here we are again.” But there is no question that equipping labs with information technology is a rapidly changing endeavor given the now-ubiquitous use of cloud computing and the soon-to-be ubiquitous deployment of ...